Literature DB >> 1269191

Disposition of digitoxin in renal failure.

H F Vöhringer, N Rietbrock, P Spurny, J Kuhlmann, H Hampl, R Baethke.   

Abstract

The disposition of digitoxin was studied for a period of 8 days in 6 uremic patients given a single oral dose of 1 mg 3H-digitoxin. In plasma, the time-course of radioactivity indicated a diminished absorption velocity of tritium compared to that of control subjects already reported and, after reaching of a pseudostate-equilibrium at 24 hr, an exponential decline with a mean half-life of 8.0 days. In urine, smaller amounts of tritiated compounds were eliminated in uremic patients (8.7% of the dose) than in controls (22.5%). The average fecal excretion of digitoxin and its metabolites was not significantly increased. Chloroform extraction and thin-layer chromatography in plasma, urine and feces suggested no qualitative alteration in the metabolism of digitoxin. Calculations of the total body tritium content (body stores) after each 24-hr interval and its pharmacokinetic behavior showed that the elimination of digitoxin is determined by the transfer constant from tissue to plasma. The differences in elimination kinetics of digitoxin and its metabolites of uremic patients and healthy subjects were not significant.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1269191     DOI: 10.1002/cpt1976194387

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

2.  Clinical pharmacokinetics of digitoxin.

Authors:  D Perrier; M Mayersohn; F I Marcus
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

3.  On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin.

Authors:  K O Haustein; R G Alken; H J Lach; U Becker; N Rietbrock
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

Review 5.  Disease-related alterations in cardiac glycoside disposition.

Authors:  H R Ochs; D J Greenblatt; G Bodem; H J Dengler
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

Review 6.  Effect of cardiopulmonary bypass on the pharmacokinetics of drugs.

Authors:  F O Holley; K V Ponganis; D R Stanski
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

7.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

8.  Relationship between dose and plasma level of digoxin and patient characteristics.

Authors:  N Heinz; N Rietbrock
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

9.  [Pharmacokinetics and cardiac effect of beta-acetyldigoxin and digitoxin in combination therapy with nifedipine].

Authors:  J Kuhlmann; S Marcin; K H Frank
Journal:  Klin Wochenschr       Date:  1984-05-15

10.  Digitoxin and its metabolites in patients with liver cirrhosis.

Authors:  A Nokhodian; S R Santos; W Kirch
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Apr-Jun       Impact factor: 2.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.